ClinicalTrials.gg
RecruitingNCT05969860Updated Nov 6, 2026

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

A Phase 2 interventional study of Clinical Encounter and Home Health Encounter in Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma and Advanced Bladder Carcinoma, sponsored by Mayo Clinic. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Mayo Clinic · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.
Updated Nov 6, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 84 studies in Multiple Myeloma by Mayo Clinic — 11 open to participants now, 16 under way, 1 of them phase 3. Multiple Myeloma · Mayo Clinic.

Planned enrollment
5th of 76
220 · median 35
Started
2023
with 3 others
Phase 2
35 of 84
4 open now
Primary completion
2027-12
later than 7 of 15 live
Registered
73rd of 84
by date

Among the 84 studies in Multiple Myeloma by Mayo Clinic, this one is the 5th largest by planned enrollment of the 76 interventional ones that give a count, is one of 4 that started in 2023, is one of 35 in phase 2, reaches primary completion later than 7 of the 15 other live ones, and was the 73rd registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

11 of the 84 studies in Multiple Myeloma by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Multiple Myeloma by Mayo Clinic, or all of them as a file.
02

Study summary

This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Currently most drug-related cancer care is conducted in infusion centers or specialty hospitals, where patients spend many hours a day isolated from family, friends, and familiar surroundings. This separation adds to the physical, emotional, social, and financial burden for patients and their families. The logistics and costs of navigating cancer treatments have become a principal contributor to patients' reduced quality of life. It is therefore important to reduce the burden of cancer in the lives of patients and their caregivers, and a vital aspect of this involves moving beyond traditional hospital and clinic-based care and evaluate innovative care delivery models with virtual capabilities. Providing cancer treatment at-home, versus in the clinic, may help reduce psychological and financial distress and increase treatment compliance, especially for marginalized patients and communities.

Read the detailed description

PRIMARY OBJECTIVE:

I. To compare mean patient-reported rating of Cancer Connected Access and Remote Expertise (CARE) using a modified question from the Consumer Assessment of Healthcare Providers and Systems (CAHPS) Cancer Care Survey after 8 weeks between patients randomized to receive care at home and care in the clinic.

SECONDARY OBJECTIVES:

I. To evaluate patient preference for location of cancer treatment administration, at the infusion center or in the home.

II. To evaluate level of comfort with receiving infusions at home based on the following measures after 24 weeks of treatment:

IIa. The proportion of patients who indicate a preference for home infusion or no preference versus outpatient infusion unit administration of cancer treatment as assessed via the Patient Preference Questionnaire; IIb. The proportion of patients who indicate comfort (quite a bit or very much) with receiving infusions at home as assessed by the Patient Preference Questionnaire.

III. To describe other patient experience questions within the Patient Preference Questionnaire after 24 weeks of treatment.

IV. To describe whether patients felt that infusions at home was worthwhile, would do it again, and recommend it to others after 24 weeks of treatment using the Was It Worth It questionnaire.

V. To test whether home-based virtual delivery of cancer directed therapy is superior to standard administration (in clinic) in patient-reported function and global health/quality of life as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core Function 17-Item (EORTC QLQ-F17) after 8 weeks of home versus outpatient infusion unit administration of cancer treatment.

VI. To test whether home-based virtual delivery of cancer directed therapy is superior to standard administration (in clinic) in patient-reported symptoms as measured by the Patient-Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE) after 8 weeks of home versus outpatient infusion unit administration of cancer treatment.

VII. To assess the safety of home administered intravenous (IV)/subcutaneous (SQ) drug treatment when administered at home by a home health provider with remote patient monitoring and Command Center support, based on the incidence, nature, severity, and attribution to the location of cancer care of the following:

VIIa. Grade 3+ adverse event (AE) clinically graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0), particularly those possibly, probably, or definitely related to the location of cancer care (i.e., at home versus in clinic).

VIII. To test whether home-based virtual delivery of cancer directed therapy is superior to standard in clinic administration in the proportion of patients with an emergency room visit or hospitalization at the end of 6 months of study treatment.

IX. Overall survival.

EXPLORATORY OBJECTIVES:

I. To assess the cost of care in first 6 months (data collected out to 1 year). II. To evaluate administration of treatment based on clinical practice data.

OUTLINE:

Patients receive at least 1 cycle of their standard of care (SOC) treatment regimen in the clinic in the absence of disease progression or unacceptable toxicity. Patients are then randomized to 1 of 2 arms.

ARM A: Patients continue receiving their SOC treatment regimen at home for approximately 24 weeks in the absence of disease progression or unacceptable toxicity. This includes drug administrations, injections/infusions and routine clinical laboratory tests in the home from the Home Health Nurse Provider (HHNP), overseen by Mayo Clinic's home health program Cancer CARE Beyond Walls (CCBW) Command Center. Patients are also provided biometric devices for health monitoring vital signs, as well as a computer tablet for video visits with the Mayo Clinic care team.

ARM B: Patients continue receiving their SOC treatment regimen in the clinic for approximately 8 weeks in the absence of disease progression or unacceptable toxicity. Patients then begin receiving their SOC treatment regimen at home as in Arm I for an approximate additional 16 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study intervention, patients are followed for 1 year.

03

Conditions studied

  • Advanced Anal Carcinoma
  • Advanced Biliary Tract Carcinoma
  • Advanced Bladder Carcinoma
  • Advanced Breast Carcinoma
  • Advanced Carcinoid Tumor
  • Advanced Cervical Carcinoma
  • Advanced Colorectal Carcinoma
  • Advanced Gastric Carcinoma
  • Advanced Glioblastoma
  • Advanced Head and Neck Carcinoma
  • Advanced HER2 Positive Breast Carcinoma
  • Advanced Lung Carcinoma
  • Advanced Lung Small Cell Carcinoma
  • Advanced Malignant Germ Cell Tumor
  • Advanced Malignant Solid Neoplasm
  • Advanced Neuroendocrine Carcinoma
  • Advanced Ovarian Carcinoma
  • Advanced Pancreatic Carcinoma
  • Advanced Prostate Small Cell Neuroendocrine Carcinoma
  • Advanced Prostate Carcinoma
  • Hematopoietic and Lymphoid System Neoplasm
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Advanced Basal Cell Carcinoma
  • Advanced Cholangiocarcinoma
  • Advanced Endometrial Carcinoma
  • Advanced Esophageal Carcinoma
  • Advanced Fallopian Tube Carcinoma
  • Advanced Hepatocellular Carcinoma
  • Advanced Liver Carcinoma
  • Advanced Lymphoma
  • Advanced Malignant Testicular Neoplasm
  • Advanced Melanoma
  • Advanced Merkel Cell Carcinoma
  • Advanced Penile Carcinoma
  • Advanced Primary Malignant Central Nervous System Neoplasm
  • Advanced Renal Cell Carcinoma
  • Advanced Sarcoma
  • Advanced Skin Squamous Cell Carcinoma
  • Advanced Urethral Carcinoma
  • Advanced Vaginal Carcinoma
  • Advanced Vulvar Carcinoma
  • Advanced Appendix Carcinoma
  • Advanced Gastroesophageal Junction Adenocarcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female or male patients with confirmed . Patients with hepatocellular carcinoma (HCC) are eligible based on imaging diagnosis along; histologic confirmation is not required.
  • Participant must be receiving a standard-of-care treatment regimen listed in this protocol that is being used in accordance with standard medical practice. Specifically, it must be either a) FDA-approved for the participant's disease indication, or b) recommended in nationally recognized professional guidelines (e.g. NCCN, ASCO, ASH, etc.) as standard of care for the disease indication. Off-label use is permitted only if supported by such guidelines.

    • Note, patients diagnosed with any of the following disease types may receive any of the eligible regimens listed. Additionally, patients receiving immunotherapy, such as nivolumab or pembrolizumab, may receive these infusions in home supplemental to any of the regimens identified. Patients may receive any combination of any above listed medications or regimens:
    • Eligible disease cancer types:

      • Anal cancer
      • Appendiceal carcinoma
      • Basal cell carcinoma
      • Bladder cancer
      • Biliary cancer
      • Breast cancer
      • Central Nervous System malignancy including glioblastoma
      • Cervical cancer
      • Cholangiocarcinoma
      • Colorectal carcinoma
      • Endometrial cancer
      • Fallopian tube cancer
      • Gastroesophageal cancer [including gastric, esophageal, and gastroesophageal junction (GEJ) cancers]
      • Germ cell carcinoma
      • Head and Neck cancer
      • Hepatocellular Carcinoma
      • Liver
      • Lung
      • Lymphoma
      • Melanoma
      • Merkel Cell
      • Multiple Myeloma
      • Myelodysplastic syndrome
      • Myeloid Disorders
      • Neuroendocrine carcinoma
      • Ovarian cancer
      • Pancreatic adenocarcinoma
      • Penile carcinoma
      • Peritoneal carcinoma
      • Prostate cancer
      • Renal cell cancer
      • Sarcoma
      • Squamous cell Carcinoma of the Skin
      • Testicular cancer
      • Urethral carcinoma
      • Vaginal carcinoma
      • Vulvar carcinoma
    • Eligible Regimens

      • Fluorouracil (5-FU) +/- leucovorin +/- bevacizumab +/- trastuzumab
      • 5FU +/- leucovorin +/- bevacizumab +/- nivolumab
      • Atezolizumab +/- bevacizumab
      • Atezolizumab +/- bevacizumab + cobimetinib, atezolizumab +/- bevacizumab + vemurafenib, atezolizumab +/- bevacizumab + cobimetinib + vemurafenib
      • Avelumab
      • Avelumab + axitinib
      • Bevacizumab
      • Bevacizumab + capecitabine
      • Bevacizumab + irinotecan (+/- capecitabine)
      • Bevacizumab + olaparib, bevacizumab + lenvatinib, bevacizumab + niraparib, bevacizumab + rucaparib
      • Bevacizumab + Temozolomide, Bevacizumab + Lomustine, or Bevacizumab + everolimus
      • Bevacizumab + trifluridine/tipiracil
      • Bortezomib
      • Bortezomib + cyclophosphamide, bortezomib + lenalidomide, bortezomib + pomalidomide, bortezomib + selinexor
      • Bortezomib + venetoclax
      • Carfilzomib
      • Carfilzomib + cyclophosphamide, carfilzomib + lenalidomide, carfilzomib + pomalidomide, carfilzomib + selinexor
      • Carfilzomib + venetoclax
      • Cemiplimab
      • Cisplatin
      • Cisplatin/5-FU
      • Cisplatin/etoposide
      • Cisplatin + durvalumab
      • Cisplatin + gemcitabine
      • Cisplatin + gemcitabine + durvalumab
      • Daratumumab (+ oral [PO] cyclophosphamide, lenalidomide, pomalidomide, or selinexor)
      • Daratumumab + bortezomib (+ PO cyclophosphamide, lenalidomide, pomalidomide, or selinexor)
      • Daratumumab + carfilzomib (+ PO cyclophosphamide, lenalidomide, pomalidomide, or selinexor)
      • Degarelix
      • Durvalumab
      • Durvalumab + tremelimumab
      • Eribulin
      • FOLFIRI +/- bevacizumab (5FU +/- leucovorin + irinotecan)
      • Fam-trastuzumab deruxtecan
      • Fulvestrant
      • Fulvestrant + ribociclib, fulvestrant + abemaciclib, fulvestrant + palbociclib, fulvestrant + alpelisib, or fulvestrant + capivasertib
      • Gemcitabine
      • Gemcitabine + durvalumab
      • Gemcitabine + paclitaxel protein-bound
      • Goserelin acetate
      • Irinotecan
      • Irinotecan + capecitabine
      • Lanreotide
      • Leuprolide
      • Nivolumab
      • Nivolumab + cabozantinib
      • Nivolumab-relatlimab
      • Octreotide
      • Paclitaxel
      • Pembrolizumab
      • Pembrolizumab + axitinib, pembrolizumab + lenvatinib, pembrolizumab + capecitabine, pembrolizumab + dabrafenib +/- trametinib, pembrolizumab + trametinib)
      • Pemetrexed
      • Pertuzumab
      • Pemetrexed + pembrolizumab
      • Rituximab
      • Trastuzumab + paclitaxel
      • Trastuzumab with or without pertuzumab maintenance (SQ or IV) (+/- tucatinib +/- capecitabine)
      • Decitabine
      • These regimens can be used only if patients are receiving one of the regimens above:

        • Darbepoetin-alfa
        • Epoetin
        • Filgrastim
  • Note: Female or male patients with histologically confirmed malignancy who are currently receiving treatment with one of the above eligible regimens may receive supportive care medications for treatment or prevention of bone , including agents such as:

    • Zoledronic acid
    • Denosumab
  • Patient has had adequate tolerability of their clinical standard of care cancer treatment in the opinion of their treating physician and no drug-related infusion reactions prior to consent
  • Patients who according to documentation from their treating provider plan to continue the treatment regimen they are currently prescribed for at least 24 weeks from the start of cycle following randomization.
  • Residing within the area serviced by supplier and paramedic network
  • Residence has wireless fidelity (wifi) to enable a reliable connection with the remote Command Center or it is suitable for connection through a wireless network solution
  • Age >= 18 years at time of registration
  • Signed form by patient
  • Willing and able to comply with the study protocol in the investigator's judgement
  • (ECOG) Performance Status (PS) 0, 1 or 2
  • Ability to complete questionnaire(s) by themselves or with assistance
  • RANDOMIZATION ELIGIBILITY CRITERIA: In addition to the criteria above, confirmation by the CCBW Command Center that the patient has adequate tolerability to the standard of care cancer therapy and no drug-related infusion reactions since pre-registration and prior to registration

Exclusion criteria

Exclusion Criteria:

  • Receiving any other agent which would be considered as a treatment for the primary neoplasm. Note: Patients are permitted concomitant standard of care oral drugs such as ribociclib, abemaciclib, or palbociclib in combination with endocrine therapy (e.g., Leuprolide, fulvestrant intramuscular [IM], etc.); tucatinib and capecitabine in combination with trastuzumab and pertuzumab for positive breast cancer; dexamethasone, cyclophosphamide, lenalidomide or pomalidomide for multiple myeloma; temozolomide, lomustine, or afinitor in combination with avastin for glioblastoma. In addition, all oral anti-hormonal agents for breast and prostate cancer are permitted (e.g., tamoxifen, arimidex, abiraterone, etc.) if used in combination with any of the drugs
  • Requiring 24/7 assistance with activities of daily living (ADLs)
  • Current inpatient hospitalization (excluding admission to the Advanced Care at Home program)
  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
  • Uncontrolled intercurrent illness including, but not limited to:

    • Ongoing or active infection
    • Symptomatic congestive heart failure
    • Unstable angina pectoris
    • Cardiac arrhythmia
    • Myocardial infarction =\< 6 months
    • Wound healing disorder
    • Or psychiatric illness/social situations that would limit compliance with study requirements
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Arm A (at-home treatment)

    Patients continue receiving their SOC treatment regimen at home for approximately 24 weeks in the absence of disease progression or unacceptable toxicity. This includes drug administrations, injections/infusions and routine clinical laboratory tests in the home from the HHNP, overseen by Mayo Clinic's home health program CCBW Command Center. Patients are also provided biometric devices for health monitoring vital signs, as well as a computer tablet for video visits with the Mayo Clinic care team.

    Other: Home Health Encounter · Other: Quality-of-Life Assessment · Other: Questionnaire Administration

  • Experimental
    Arm B (clinic & at-home treatment)

    Patients continue receiving their SOC treatment regimen in the clinic for approximately 8 weeks in the absence of disease progression or unacceptable toxicity. Patients then begin receiving their SOC treatment regimen at home as in Arm I for an approximate additional 16 weeks in the absence of disease progression or unacceptable toxicity.

    Procedure: Clinical Encounter · Other: Home Health Encounter · Other: Quality-of-Life Assessment · Other: Questionnaire Administration

Interventions

  • ProcedureClinical Encounter

    Receive treatment in clinic

    Also known as: Patient Encounter

  • OtherHome Health Encounter

    Receive at-home treatment

    Also known as: HH, Home, Home Care Visit, Home Health

  • OtherQuality-of-Life Assessment

    Ancillary studies

    Also known as: Quality of Life Assessment

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Mean patient-reported rating of Cancer Connected Access and Remote Expertise

    This hypothesis test will use patient ratings from a single 0-10 item from the Consumer Assessment of Healthcare Providers and Systems Cancer Care Survey assessing "your overall cancer care experience". Will be compared between arms using a two-sample t-test.

    Time frame: At 8 weeks

Secondary outcomes

  1. Patient-preferred treatment location

    The proportion of patients who preferred care at home or expressed no preference will be computed and compared to 50% using a one-group test of proportions. Additional Likert patient feedback questions and "Was It Worth It" questions at each time point will be described using frequencies and relative frequencies by arm (or overall if applicable) and compared between arms (if applicable) using chi-squared tests. Numeric analog scale questions will be described using means and standard deviations and compared between arms (if applicable) using t-tests.

    Time frame: At 24 weeks

  2. Patient level of comfort with receiving infusions at home

    Patient responses to comfort level with receiving infusions at home will be described using frequencies and relative frequencies. The proportion of patients who express comfort (quite a bit or very much) will also be tabulated and a proportion greater than 70% will signify acceptance. Additional Likert patient feedback questions and "Was It Worth It" questions at each time point will be described using frequencies and relative frequencies by arm (or overall if applicable) and compared between arms (if applicable) using chi-squared tests. Numeric analog scale questions will be described using means and standard deviations and compared between arms (if applicable) using t-tests.

    Time frame: At 24 weeks

  3. Patient-reported worthwhileness

    Measured by the Was it Worth It questionnaire. The Was It Worth It questionnaire asks patients whether they thought that receiving chemo/infusions at home was worthwhile, whether they would do it again, and whether they would recommend it to others.

    Time frame: At 24 weeks

  4. Patient-reported function

    Measured by the European Organization for Research and Treatment of Cancer. Mean and standard deviation of each scale will be computed by arm. Means and standard deviations of each scale will also be computed at all other assessment time points. Mean changes from baseline in each scale at 8 weeks (and other assessment time points) will be compared between arms using a linear combination of parameters from a general linear mixed model. Each model will include all available data from all time points. Fixed effects will include arm, time point, and arm-by-time point interaction. Repeated observations by patient will be modeled using compound symmetric correlation structure over time. Such values as the mean change from baseline at 8 weeks by arm, and difference in mean change from baseline at 8 weeks between arms will be estimated with confidence intervals based on the mixed model. Comparisons at other time points will also be carried out and graphically displayed using mean plots.

    Time frame: At 8 weeks

  5. Patient-reported symptoms

    Will be measured by the Patient-Reported Outcomes-Common Terminology Criteria for Adverse Events (CTCAE) and summarized using composite grades. The baseline adjustment approach will be applied and resulting maximum baseline-adjusted grade will be reported by symptomatic adverse events (AE) as the proportion of patients with at least one grade \>=1 AE during the first 8 weeks. The proportion of patients with at least one grade \>= 3 AE per symptomatic AE will also be tabulated during the first 8 weeks. Comparisons between arms will employ Fisher's exact tests. Additional summaries over the 24 weeks by tables and graphics will also be generated.

    Time frame: At 8 weeks

  6. Patient-reported side effect impact

    Will be measured by the General Physical-5 (GP5). The frequency and relative frequency of patient responses to the GP5 at 8 weeks will be computed by arm and compared between arms using a chi-squared test. The categorical analysis will also be computed at other assessment time points. Mean GP5 scores over time will also be explored using a general linear mixed model and mean plots.

    Time frame: At 8 weeks

  7. Incidence of adverse events

    The maximum grade for each type of adverse event will be summarized using CTCAE version 5.0. The frequency and percentage of grade 3+ adverse events (by individual AEs and overall) will be reported by arm and compared between arms using a Fisher's exact test.

    Time frame: Up to 24 weeks

  8. Emergency room visits and hospitalizations

    The proportion of patients with an emergency room visit or hospitalization will be computed per arm and compared between arms using a Fisher's exact test. In subsequent analyses, emergency room visits and hospitalizations will be explored separately. Proportion of patients with emergency room visits or hospitalizations will also be summarized over the entire study.

    Time frame: At 8 weeks

  9. Overall survival

    Will be estimated using the Kaplan-Meier method and compared between arms using a log-rank test.

    Time frame: The time from study entry to death from any cause, assessed up to 1 year after completion of study intervention

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Dec 2027, 50 months after the start.

Of 411 non-industry phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's planned 50 months is below that.

Counting every sponsor, half of 504 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Aug 2023 → Sep 2023, primary completion Jan 2027 → Dec 2027 and completion Jan 2027 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2023
First posted
Aug 1, 2023
StartActual
Sep 21, 2023was Aug 2023
Primary completionEst.
Dec 1, 2027was Jan 2027
CompletionEst.
Mar 22, 2028was Jan 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 23, 2023→Sep 21, 2023
Nov 6, 2026
Primary completion
Jan 1, 2027→Dec 1, 2027
Nov 6, 2026
Study completion
Jan 1, 2027→Mar 22, 2028
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Start date Aug 23, 2023→Sep 21, 2023
    Primary completion Jan 1, 2027→Dec 1, 2027
    Study completion Jan 1, 2027→Mar 22, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05969860
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
Aug 1, 2023
Start date
Sep 21, 2023
Primary completion
Dec 1, 2027 (estimated)
Completion
Mar 22, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Clinical Trials Referral Office
Contact
mayocliniccancerstudies@mayo.edu
855-776-0015
Roxana S. Dronca, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion